Clinical data | |
---|---|
Trade names | Conjupri, others |
AHFS/Drugs.com | Monograph |
License data | |
Routes of administration | Oral |
ATC code | |
Pharmacokinetic data | |
Protein binding | 93% |
Metabolism | Liver |
Excretion | 60% of the metabolites excreted in the urine |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C20H25ClN2O5 |
Molar mass | 408.88 g·mol−1 |
3D model (JSmol) | |
| |
|
Levamlodipine (INN), also known as levoamlodipine or S-amlodipine is a pharmacologically active enantiomer of amlodipine.[1] Amlodipine belongs to the dihydropyridine group of calcium channel blocker used as an antihypertensive and antianginal agent.[2] It was approved by the U.S. FDA in December 2019 and is currently marketed under the brand name Conjupri.[3]